Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Director departure
Quarterly results
Appointed director
Cardiff Oncology, Inc. (TROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Investor presentation
Docs: "Pancreatic Cancer and Small Cell Lung Cancer Program Updates Metastatic Pancreatic Ductal Adenocarcinoma",
"Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy Pancreatic Cancer Program"
08/09/2023 8-K Quarterly results
Docs: "CARDIFF ONCOLOGY, INC. CERTIFICATE OF ELIMINATION",
"Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update"
08/07/2023 8-K Investor presentation
Docs: "Investor Contact:"
07/24/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"
02/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib"
11/03/2022 8-K Quarterly results
10/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "G2 G1 M S PLK1"
09/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer at the ESMO Congress 2022 Durable responses to treatment, with a median duration of response of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC",
"Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer , Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates Next trial in RAS-mutated mCRC is a randomized Phase 2 trial to demonstrate onvansertib’s contribution to SoC and position for a possible accelerated approval opportunity&#59; topline data expected in 2H 2024",
"CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING"
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022"
08/04/2022 8-K Quarterly results
Docs: "Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates"
06/14/2022 8-K/A Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Cardiff Oncology Announces Departure of Chief Medical Officer"
04/08/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting",
"Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models"
02/24/2022 8-K Quarterly results
01/31/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635"
01/18/2022 8-K Investor presentation
Docs: "Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival",
"Mark Erlander, Ph.D. Chief Executive Officer 20222021 2008 2013 2017 20222021 2008 2013 2017"
01/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs –Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli Lilly and Company, and director of Pfizer Oncology Research Unit"
12/10/2021 8-K Quarterly results
12/03/2021 8-K Quarterly results
11/18/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "-1-",
"SECURITIES PURCHASE AGREEMENT",
"Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative"
11/10/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences"
11/04/2021 8-K Quarterly results
Docs: "Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates"
09/08/2021 8-K Quarterly results
09/07/2021 8-K Quarterly results
08/25/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
07/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"-1-"
07/06/2021 8-K Quarterly results
06/28/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy